MORE►
Spectral MD
Spectral MD's DeepView device [Photo: Spectral AI]
Spectral MD Awarded BARDA Project BioShield Contract Worth Up to $149M
by David Seeley | Sep 28, 2023
The contract is for the advanced development of Spectral MD's DeepView System, an AI-driven burn wound imaging device designed to be used at emergency departments, trauma centers, and burn centers.
by David Seeley |
Aug 29, 2023
With $130 million in government funding supporting its AI-powered wound-prediction tech as a triage tool for burn victims in a mass casualty event, Dallas-based Spectral MD is nearing its listing on Nasdaq via a SPAC merger. Its listing as "Spectral AI" is slated for September 8 or 11, and the company offered updates on how it's going—revealing the nuts & bolts of how such transactions work.
MORE►
by Lance Murray |
Apr 12, 2023
Spectral MD Holdings, founded over a decade ago, is a predictive analytics company focused on wound care treatment. It plans to delist from the AIM market and list on Nasdaq via a SPAC merger, operating as Spectral AI. The company’s AI-enabled FDA Breakthrough Designated DeepView platform uses AI algorithms and "difficult-to-duplicate" imaging technology to provide healing assessments.
MORE►
by Lance Murray |
Jul 24, 2019
Spectral's device uses real-time data and artificial intelligence to help look beneath the skin's surface and assess wound and burn damage, which can help doctors improve treatments and outcomes — as well as be a tool in the response to mass burn casualties in a national emergency.
MORE►
